B7-h3 directed antibody drug conjugates

Abstract

The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain (VH) Domains that have been humanized and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to recipient subjects. The invention particularly pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules, etc. that comprise: (i) such B7-H3-binding Variable Domains and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention is also directed to pharmaceutical compositions that contain any of such B7-H3-binding molecules, and to methods involving the use of any of such B7-H3-binding molecules in the treatment of cancer and other diseases and conditions. The invention also particularly pertains to a molecule that comprises the human B7-H3 binding domain of a humanized anti-human B7-H3 antibody conjugated to at least one drug moiety (a “B7-H3-ADC”). The invention is also directed to pharmaceutical compositions that contain such B7-H3-ADCs, and to methods involving the use of any of such B7-H3-ADCs in the treatment of cancer and other diseases and conditions.

1 - 32 . (canceled) 
     
     
         33 . An anti B7-H3 antibody drug conjugate (B7-H3-ADC) that comprises the formula:
   Ab-(LM) m -(D) n ,   wherein:   Ab is a humanized B7-H3 antibody or B7-H3 binding fragment thereof that binds to B7-H3 and comprises:   (i) the CDR L 1 sequence RASESIYSYLA, the CDR L 2 sequence NTKTLPE and the CDR L 3 sequence QHHYGTPPWT in its Variable Light Chain (VL) domain; and   (ii) the CDR H 1 sequence SYGMS, the CDR H 2 sequence TINSGGSNTYYPDSLKG and the CDR H 3 sequence HDGGAMDY in its Variable Heavy Chain (VH) domain;   D is a cytotoxic drug moiety that comprises a duocarmycin cytotoxin;   LM comprises at least one bond or a Linker Molecule that covalently links Ab and D;   m is an integer between 0 and n and denotes the number of Linker Molecules of the B7-H3-ADC;
 and 
   n is an integer between 1 and 10 and denotes the number of cytotoxic drug moieties covalently linked to the B7-H3-ADC molecule.   
     
     
         34 . The B7-H3-ADC of  claim 33 , wherein said Ab comprises:
 (i) a humanized Variable Light Chain (VL) domain comprising the amino acid sequence of SEQ ID NO: 20; and   (ii) a humanized Variable Heavy Chain (VH) domain comprising the amino acid sequence of SEQ ID NO: 21;   
     
     
         35 . The B7-H3-ADC of  claim 34 , wherein said Ab further comprises an Fe domain of a human IgG. 
     
     
         36 . The B7-H3-ADC of  claim 35 , wherein said human IgG is a human IgG1, IgG2, IgG3, or IgG4. 
     
     
         37 . The B7-H3-ADC of  claim 35 , wherein said human IgG is a human IgG1. 
     
     
         38 . The B7-H3-ADC of  claim 35 , wherein said Fc Domain is a variant Fc Domain that comprises:
 (a) one or more amino acid modifications that reduces the affinity of the variant Fc Domain for an FcγR; and/or   (b) one or more amino acid modifications that enhances the serum half-life of the variant Fc Domain.   
     
     
         39 . The B7-H3-ADC of  claim 38 , wherein said modifications that reduce the affinity of the variant Fc Domain for an FcγR comprise the substitution of L234A; L235A; or L234A and L235A, wherein the numbering is that of the EU index as in Kabat. 
     
     
         40 . The B7-H3-ADC of  claim 38 , wherein said modifications that enhance the serum half-life of the variant Fc Domain comprise the substitution of M252Y; M252Y and S254T; M252Y and T256E; M252Y, S254T and T256E; or K288D and H435K, wherein the numbering is that of the EU index as in Kabat. 
     
     
         41 . The B7-H3-ADC of  claim 33 , wherein at least one of said LM moieties is a Linker Molecule. 
     
     
         42 . The B7-H3-ADC of  claim 41 , wherein said LM Linker Molecule comprises a cleavable linker. 
     
     
         43 . The B7-H3-ADC of  claim 42 , wherein said cleavable linker is a peptidic linker. 
     
     
         44 . The B7-H3-ADC of  claim 43 , wherein said peptidic linker is a valine-citrulline dipeptide linker. 
     
     
         45 . The B7-H3-ADC of  claim 42 , wherein said LM Linker Molecule further comprises a self-eliminating spacer between the cleavable linker and D. 
     
     
         46 . The B7-H3-ADC of  claim 45 , wherein said self-eliminating spacer comprises a para-aminobenzyloxycarbonyl moiety. 
     
     
         47 . The B7-H3-ADC of  claim 42 , wherein said Linker Molecule further comprises a maleimide linker moiety between the cleavable linker and Ab. 
     
     
         48 . The B7-H3-ADC of  claim 40 , wherein LM comprises the formula:
   [V-(W) k -(X) 1 -A]   and said conjugate comprises the formula:
   Ab-[V-(W) k -(X) 1 -A]-D 
   wherein:   V is a cleavable linker,   (W) k -(X) 1 -A is an elongated, self-eliminating spacer system, that self-eliminates via a 1, (4+2n)-elimination,   W and X are each a 1, (4+2n) electronic cascade spacer, being the same or different,   A is either a spacer group of formula (Y) m , wherein Y is a 1, (4+2n) electronic cascade spacer, or a group of formula U, being a cyclisation elimination spacer,   k, l and m are independently an integer of 0 (included) to 5 (included),   n is an integer of 0 (included) to 10 (included),   with the provisos that:
 when A is (Y) m : then k+l+m≥1, and 
 if k+l+m=1, then n>l; 
 when A is U: then k+1≥1, 
   W, X, and Y are independently selected from compounds having the formula:   
       
         
           
           
               
               
           
         
         or the formula: 
       
       
         
           
           
               
               
           
         
         wherein: Q is —R 5 C═CR 6 —, S, O, NR 5 , —R 5 C═N—, or —N═CR 5 —
 P is NR 7 , O or S 
 a, b, and c are independently an integer of 0 (included) to 5 (included); 
 I, F and G are independently selected from compounds having the formula: 
 
       
       
         
           
           
               
               
           
         
         wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9  independently represent H, C 1-6  alkyl, C 3-20  heterocyclyl, C 5-20  aryl, C 1-6  alkoxy, hydroxy (OH), amino (NH 2 ), mono-substituted amino (NR x H), di-substituted amino (NR x   1 R x   2 ), nitro (NO 2 ), halogen, CF 3 , CN, CONH 2 , SO 2 Me, CONHMe, cyclic C 1-5  alkylamino, imidazolyl, C 1-6  alkylpiperazinyl, morpholino, thiol (SH), thioether (SR x ), tetrazole, carboxy (COOH), carboxylate (COOR x ), sulphoxy (S(═O) 2 OH), sulphonate (S(═O) 2 OR x ), sulphonyl (S(═O) 2 R x ), sulphixy (S(═O)OH), sulphinate (S(═O)OR x ), sulphinyl (S(═O)R x ), phosphonooxy (OP(═O)(OH) 2 ), and phosphate (OP(═O)(OR x ) 2 ), where R x , R x   1  and R x   2  are independently selected from a C 1-6  alkyl group, a C 3-20  heterocyclyl group or a C 5-20  aryl group, two or more of the substituents R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , or R 9  optionally being connected to one another to form one or more aliphatic or aromatic cyclic structures; 
         U is selected from compounds having the formula: 
       
       
         
           
           
               
               
           
         
         wherein: 
         a, b and c are independently selected to be an integer of 0 or 1;
 provided that a +b+c=2 or 3; 
 
         R 1  and/or R 2  independently represent H, C 1-6  alkyl, the alkyl being optionally substituted with one or more of the following groups: hydroxy (OH), ether (OR x ), amino (NH 2 ), mono-substituted amino (NR x H), disubstituted amino (NR x   1 R x   2 ), nitro (NO 2 ), halogen, CF 3 , CN, CONH 2 , SO 2 Me, CONHMe, cyclic C 1-5  alkylamino, imidazolyl, C 1-6  alkylpiperazinyl, morpholino, thiol (SH), thioether (SR x ), tetrazole, carboxy (COOH), carboxylate (COOR x ), sulphoxy (S(═O) 2 OH), sulphonate (S(═O) 2 OR x ), sulphonyl (S(═O) 2 R x ), sulphixy (S(═O)OH), sulphinate (S(═O)OR x ), sulphinyl (S(═O)R x ), phosphonooxy (OP(═O)(OH) 2 ), and phosphate (OP(═O)(OR x ) 2 ), where R x , R x   1  and R x   2  are selected from a C 1-6  alkyl group, a C 3-20  heterocyclyl group or a C 5-20  aryl group; and 
         R 3 , R 4 , R 5 , R 6 , R 7  and R 8  independently represent H, C 1-6  alkyl, C 3-20  heterocyclyl, C 5-20  aryl, C 1-6  alkoxy, hydroxy (OH), amino (NH 2 ), mono-substituted amino (NR x H), disubstituted amino (NR x   1 R x   2 ), nitro (NO 2 ), halogen, CF 3 , CN, CONH 2 , SO 2 Me, CONHMe, cyclic C 1-5  alkylamino, imidazolyl, C 1-6  alkylpiperazinyl, morpholino, thiol (SH), thioether (SR x ), tetrazole, carboxy (COOH), carboxylate (COOR x ), sulphoxy (S(═O) 2 OH), sulphonate (S(═O) 2 OR x ), sulphonyl (S(═O) 2 R x ), sulphixy (S(═O)OH), sulphinate (S(═O)OR x ), sulphinyl (S(═O)R x ), phosphonooxy (OP(═O)(OH) 2 ), and phosphate (OP(═O)(OR x ) 2 ), where R x , R x   1  and R x   2  are selected from a C 1-6  alkyl group, a C 3-20  heterocyclyl group or a C 5-20  aryl group, and two or more of the substituents R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , or R 8  are optionally connected to one another to form one or more aliphatic or aromatic cyclic structures. 
       
     
     
         49 . The B7-H3-ADC of  claim 48 , wherein said LM linker molecule comprises:
 (1) p-aminobenzyloxycarbonyl-p-aminobenzyloxycarbonyl;   (2) p-aminobenzyloxycarbonyl-p-aminobenzyloxycarbonyl-p-aminobenzyloxycarbonyl;   (3) p-ammocinnamyloxycarbonyl;   (4) p-aminocinnamyloxycarbonyl-p-aminobenzyloxycarbonyl;   (5) p-amino-benzyloxycarbonyl-p-aminocinnamyloxycarbonyl;   (6) p-aminocinnamyloxycarbonyl-p-aminocinnamyloxycarbonyl;   (7) p-aminophenylpentadienyloxycarbonyl;   (8) p-aminophenylpentadienyloxycarbonyl-p-arninocinnamyloxycarbonyl;   (9) p-aminophenylpentadienyloxycarbonyl-paminobenzyloxycarbonyl;   (10) p-aminophenylpentadienyloxycarbonyl-p-aminophenylpentadienyloxycarbonyl;   (11) p-aminobenzyloxycarbonyl(methylamino)ethyl(methylamino) carbonyl;   (12) p-aminocinnamyloxycarbonyl(methylamino)ethyl(methylamino) carbonyl;   (13) p-aminobenzyloxycarbonyl-p-aminobenzyloxycarbonyl(methylamino) ethyl(methylamino)carbonyl;   (14) p-aminocinnamyloxycarbonyl-p-aminobenzyloxycarbonyl (methylamino)ethyl(methylamino)carbonyl;   (15) p-aminobenzyloxycarbonyl-p-arninocinnamyloxycarbonyl (methylamino)ethyl(methylamino)-carbonyl;   (16) p-aminocinnamyloxycarbonyl-p-aminocinnamyloxycarbonyl (methylamino)ethyl(methylamino)carbonyl;   (17) p-aminobenzyloxycarbonyl-p-aminobenzyl;   (18) p-aminobenzyloxycarbonyl-p-aminobenzyloxycarbonyl-p-aminobenzyl;   (19) p-aminocinnamyl;   (20) p-aminocinnamyloxycarbonyl-p-aminobenzyl;   (21) p-aminobenzyloxycarbonyl-p-aminocinnamyl;   (22) p-amino-cinnamyloxycarbonyl-p-aminocinnamyl;   (23) p-aminophenylpentadienyl;   (24) p-aminophenylpentadienyloxycarbonyl-p-aminocinnamyl;   (25) p-aminophenylpentadienyloxycarbonyl-p-aminobenzyl; or   (26) p-aminophenylpentadienyloxycarbonyl-p-aminophenylpentadienyl.   
     
     
         50 . The B7-H3-ADC of  claim 41 , wherein said LM Linker Molecule is conjugated to the side chain of an amino acid of a polypeptide chain of Ab and binds the Ab to a molecule of the cytotoxic drug moiety D. 
     
     
         51 . The B7-H3-ADC of  claim 33 , wherein said duocarmycin cytotoxin is selected from the group consisting of: duocarmycin A, duocarmycin B1, duocarmycin B2, duocarmycin C1, duocarmycin C2, duocarmycin D, duocarmycin SA, CC-1065, adozelesin, bizelesin, carzelesin (U-80244), seco-duocarmycin and spiro-duocarmycin (DUBA). 
     
     
         52 . The B7-H3-ADC of  claim 51 , wherein said duocarmycin cytotoxin is seco-duocarmycin. 
     
     
         53 . The B7-H3-ADC of  claim 41 , wherein said LM Linker Molecule is covalently linked to the Ab via reduced inter-chain disulfides. 
     
     
         54 . The B7-H3-ADC of  claim 33 , wherein said antibody or said B7-H3 binding fragment thereof comprises a human IgG Constant Domain Kappa Domain. 
     
     
         55 . The B7-H3-ADC of  claim 54 , wherein said human IgG Constant Domain Kappa Domain comprises the amino acid sequence of SEQ ID NO:1. 
     
     
         56 . The B7-H3-ADC of  claim 55 , wherein:
 Ab is said antibody and said antibody comprises:
 (i) a light chain comprising the Variable Light Chain (VL) domain comprising the amino acid sequence of SEQ ID NO:20 and a CL Kappa Domain of SEQ ID NO:1; and 
 (ii) a heavy chain comprising the Variable Heavy Chain (VH) domain comprising the amino acid sequence of SEQ ID NO:21, a CH1 Domain of SEQ ID NO:3, a Hinge Domain of SEQ ID NO:7 and a Fc Domain comprising a CH2-CH3 Domain of SEQ ID NO:12; and 
   said LM comprises a Linker Molecule comprising a maleimide linker moiety, a valine-citrulline dipeptide linker, and a para-aminobenzyloxycarbonyl moiety.   
     
     
         57 . A pharmaceutical composition comprising an effective amount of the B7-H3-ADC of  claim 33  and a pharmaceutically acceptable carrier, excipient or diluent. 
     
     
         58 . A pharmaceutical composition comprising an effective amount of the B7-H3-ADC of  claim 57  and a pharmaceutically acceptable carrier, excipient or diluent.